GlobeImmune, Inc. recently announced the successful closing of a Series B stock financing raising $34.3 million, to enable continued development of their two lead Tarmogen™ products in the oncology and infectious disease segments.
The Series B was led by Lilly Ventures along with Medica Venture Partner, Adams Street Partners, Biogen Idec, Inc., Genentech, Inc., Partners Healthcare and GC&H Investments. In addition, all of the A round investors, HealthCare Ventures, LLC, Morgenthaler Ventures and Sequel Venture Partners, also participated.
This brings the September total capital raised in Colorado to nearly $225 million (GlobeImmune, $34.3 million, Replidyne $62.5 million and Myogen $116.4 million). A very good sign indeed, though just scratching the surface of what is yet to come from the Rocky Mountain state.
Sunday, September 25, 2005
Catching the Eye of Costal VC’s and IB’s
Posted by Adam at 1:35 PM
Subscribe to:
Post Comments (Atom)
2 comments:
Post a Comment